A First-in-Human, Single Ascending Dose and Pharmacokinetic/Pharmacodynamic Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of Intravenous Infusions of E2025 in Healthy Subjects
Overview
- Phase
- Phase 1
- Intervention
- E2025
- Conditions
- Healthy Volunteers
- Sponsor
- Eisai Inc.
- Enrollment
- 32
- Locations
- 1
- Primary Endpoint
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
The primary purpose of the study is to evaluate the safety and tolerability of single intravenous (IV) infusions of E2025 in healthy adult participants.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Non-smoking, male or female age greater than or equal to (\>=) 18 years and less than or equal to (\<=) 55 years old at the time of informed consent. Females must be of nonchildbearing potential
- •Body weight \>=50 kilogram (kg) and a Body Mass Index (BMI) \>=18 and less than (\<) 30 kilogram per square meter (kg/m\^2) at Screening
Exclusion Criteria
- •Females who are breastfeeding or pregnant at Screening or Baseline; Females of childbearing potential.
- •Males who have not had a successful vasectomy (confirmed azoospermia) if their female partners are of childbearing potential and are not willing to use a highly effective contraceptive method throughout the study period or for 203 days after their partner's study drug administration.
- •Clinically significant illness that requires medical treatment within 8 weeks or a clinically significant infection that requires medical treatment within 4 weeks of dosing
- •Evidence of disease that may influence the outcome of the study within 4 weeks before dosing; example, psychiatric disorders and disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, or cardiovascular system, or participants who have a congenital abnormality in metabolism
- •Any clinically abnormal symptom or organ impairment found by medical history at Screening, and physical examinations, vital signs, ECG finding, or laboratory test results that require medical treatment at Screening
- •A prolonged QT/QTc interval (QTcF \>450 millisecond \[ms\]). A history of risk factors for torsade de pointes or the use of concomitant medications that prolonged the QT/QTc interval
- •Persistent systolic blood pressure (BP) greater than 130 millimeter of mercury (mmHg) or diastolic BP greater than 85 mmHg at Screening or Baseline; Heart rate less than 50 or more than 100 beats per minute at Screening or Baseline
- •Any lifetime history of suicidal ideation or any lifetime history of suicidal behavior as indicated by the Columbia-suicide Severity Rating Scale (C-SSRS) or equivalent scale or via interview with a psychiatrist
- •Any lifetime history of psychiatric disease (including but not limited to depression or other mood disorders, bipolar disorder, psychotic disorders, including schizophrenia, panic attacks, anxiety disorders); any current psychiatric symptoms as indicated by a standard screening tool.
- •Known history of clinically significant drug allergy; known history of food allergies or presently experiencing significant seasonal or perennial allergy at Screening
Arms & Interventions
Part A, Cohort 1: E2025 Dose 1 or Placebo
Participants will receive E2025 Dose 1 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
Intervention: E2025
Part A, Cohort 1: E2025 Dose 1 or Placebo
Participants will receive E2025 Dose 1 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
Intervention: Placebo
Part A, Cohort 2: E2025 Dose 2 or Placebo
Participants will receive E2025 Dose 2 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
Intervention: E2025
Part A, Cohort 2: E2025 Dose 2 or Placebo
Participants will receive E2025 Dose 2 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
Intervention: Placebo
Part A, Cohort 3: E2025 Dose 3 or Placebo
Participants will receive E2025 Dose 3 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
Intervention: E2025
Part A, Cohort 3: E2025 Dose 3 or Placebo
Participants will receive E2025 Dose 3 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
Intervention: Placebo
Part A, Cohort 4: E2025 Dose 4 or Placebo
Participants will receive E2025 Dose 4 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
Intervention: E2025
Part A, Cohort 4: E2025 Dose 4 or Placebo
Participants will receive E2025 Dose 4 or E2025 matching placebo (normal saline) administered as an IV infusion on Day 1.
Intervention: Placebo
Part B, Cohort 5: E2025 Dose 2
Participants will receive E2025 Dose 2 administered as an IV infusion on Day 1.
Intervention: E2025
Part B, Cohort 6: E2025 Dose 3
Participants will receive E2025 Dose 3 administered as an IV infusion on Day 1.
Intervention: E2025
Part B Cohort 7: E2025 Dose 4
Participants will receive E2025 Dose 4 administered as an IV infusion on Day 1.
Intervention: E2025
Outcomes
Primary Outcomes
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time Frame: Screening up to Day 113
Number of Participants With Clinically Significant Abnormal Laboratory Values
Time Frame: Screening up to Day 113
Number of Participants With Clinically Significant Abnormal Vital Signs Values
Time Frame: Screening up to Day 113
Number of Participants With Clinically Significant Abnormal Electrocardiograms (ECGs) Findings
Time Frame: Screening up to Day 113
Number of Participants With Clinically Significant Abnormal Physical Examinations Findings
Time Frame: Screening up to Day 113
Number of Participants With Clinically Significant Abnormal Psychiatric Examination Findings
Time Frame: Screening up to Day 8
Secondary Outcomes
- Part A: Cerebrospinal Fluid (CSF) Concentrations for E2025(Pre-dose; Days 8 and 29 post-dose)
- Part B, CSF Cmax: Maximum Observed CSF Concentration for E2025(Day 1: 0-24 hours up to Day 99)
- Part B, CSF Tmax: Time to Reach Maximum Observed CSF Concentration (Cmax) for E2025(Day 1: 0-24 hours up to Day 99)
- Part B, CSF AUC(0-24h): Area Under the CSF Concentration-time Curve From Time Zero to 24 hours for E2025(Day 1: 0-24 hours)
- Part B: Ratio of Cmax in CSF and Cmax in Serum for E2025(Day 1: 0-24 hours up to Day 99)
- Part B: Ratio of AUC(0-24h) in CSF and AUC(0-24h) in Serum for E2025(Day 1: 0-24 hours)
- Serum Concentration of Anti- E2025 Antibodies(Day 1 up to Day 113)
- Cmax: Maximum Observed Serum Concentration for E2025(Day 1: 0-24 hours up to Day 113)
- Tmax: Time to Reach Maximum Observed Serum Concentration (Cmax) for E2025(Day 1: 0-24 hours up to Day 113)
- AUC(0-t): Area Under the Serum Concentration-time Curve From Time Zero to Last Quantifiable Concentration for E2025(Day 1: 0-24 hours up to Day 113)
- AUC(0-inf): Area Under the Serum Concentration-time Curve From Time Zero to Infinite for E2025(Day 1: 0-24 hours up to Day 113)
- AUC(0-24h): Area Under the Serum Concentration-time Curve From Time Zero to 24 hours for E2025(Day 1: 0-24 hours)
- AUC(0-72h): Area Under the Serum Concentration-time Curve From Time Zero to 72 hours for E2025(Day 1: 0-72 hours)
- AUC(0-672h): Area Under the Serum Concentration-time Curve From Time Zero to 672 hours for E2025(Day 1: 0-672 hours)
- t1/2: Terminal Elimination Phase Half-life for E2025(Day 1: 0-24 hours up to Day 113)
- CL/F: Apparent Total Clearance for E2025(Day 1: 0-24 hours up to Day 113)
- Vss: Volume of Distribution at Steady State for E2025(Day 1: 0-24 hours up to Day 113)